DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fv2dk3/global_and) has announced the addition of the "Global and Chinese Insulin Industry Report, 2013-2017" report to their offering.
As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 382 million in 2013 at a compound annual growth rate of 7.6%. And insulin as the important diabetes medication has also seen increasing market size. In 2012 the global insulin market size reached US$20.8 billion, a year-on-year rise of 12.9%, basically monopolized by Novo Nordisk, Sanofi and Eli Lilly, which altogether accounted for 88.7% of market share.
Being the biggest diabetes power in the world, China currently has 98.4 million patients, accounting for about 25.8% of the world's total. With the maturing of national health insurance system and improvement of economic level, the Chinese insulin drug market size has been on the rise, with the CAGR in 2007-2012 up to 25.4%, well above that of the global insulin market size, and it is expected to maintain a CAGR of at least 15% in the next few years.
Insulin has seen an increasing proportion of Chinese diabetes drug market, from 38.7% in 2007 to 55.6% in 2012. However, due to technical barriers, China's insulin market is mainly occupied by Novo Nordisk, Sanofi and Eli Lilly, of which, Novo Nordisk accounted for 60.3% in 2012. While in recombinant human insulin market segments, the local Chinese enterprise -Tonghua Dongbao Pharmaceutical Co., Ltd. occupied part of the market with approximately 16% share.
Attracted by China's tremendous diabetes drug market, multinational companies like Bayer, United Laboratories as well as the local Wanbang Biopharmaceuticals and Hisun Pharmaceutical are speeding up layout in China's insulin market. Among them, Bayer Schering Pharma has obtained exclusive marketing and distribution rights of Poland's Bioton insulin product SciLin in China as early as 2009; the recombinant Lispro Insulin of Wanbang Biopharmaceuticals has also received clinical approval issued by SFDA in September 2013.
Key Topics Covered
1. Overview of Insulin
2. Development of Global Insulin Market
3. Development of China Insulin Market
4. Key Insulin Companies
5. Summary and Forecast
Companies Mentioned
- Dongbao
- Eli Lilly
- Gan & Lee
- Novo Nordisk
- Sanofi
- Wanbang Biopharmaceuticals
- Xinbai Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/fv2dk3/global_and
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
